WO2023004415A3 - Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments - Google Patents
Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments Download PDFInfo
- Publication number
- WO2023004415A3 WO2023004415A3 PCT/US2022/074048 US2022074048W WO2023004415A3 WO 2023004415 A3 WO2023004415 A3 WO 2023004415A3 US 2022074048 W US2022074048 W US 2022074048W WO 2023004415 A3 WO2023004415 A3 WO 2023004415A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- cov
- sars
- bacterial spores
- antigenic fragments
- Prior art date
Links
- 229940022962 COVID-19 vaccine Drugs 0.000 title abstract 3
- 230000000890 antigenic effect Effects 0.000 title 1
- 210000004666 bacterial spore Anatomy 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 244000063299 Bacillus subtilis Species 0.000 abstract 1
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 101710094648 Coat protein Proteins 0.000 abstract 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 101710083689 Probable capsid protein Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed are compositions comprising a SARS-CoV-2 vaccine that can be administered orally. The vaccine can be on a platform comprising a spore coat protein from a spore forming bacteria, such as Bacillus subtilis. Also disclosed are methods of preventing or treating a COVID-19 infection comprising providing the SARS-CoV-2 vaccine to a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163224638P | 2021-07-22 | 2021-07-22 | |
US63/224,638 | 2021-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023004415A2 WO2023004415A2 (en) | 2023-01-26 |
WO2023004415A3 true WO2023004415A3 (en) | 2023-03-02 |
Family
ID=84978769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/074048 WO2023004415A2 (en) | 2021-07-22 | 2022-07-22 | Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023004415A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023094713A2 (en) * | 2021-11-29 | 2023-06-01 | BioNTech SE | Coronavirus vaccine |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050221423A1 (en) * | 2002-04-10 | 2005-10-06 | Andersen Jens T | Bacillus host cell |
KR102157964B1 (en) * | 2019-06-13 | 2020-09-22 | (주)제이비바이오텍 | African swine fever vaccine of porcine using CRISPR/Cas9 based Bacillus subtilis genome editing mechanism |
WO2021019102A2 (en) * | 2019-08-01 | 2021-02-04 | Acm Biolabs Pte Ltd | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes |
US11054429B1 (en) * | 2020-03-25 | 2021-07-06 | National University Of Singapore | SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein binding |
-
2022
- 2022-07-22 WO PCT/US2022/074048 patent/WO2023004415A2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050221423A1 (en) * | 2002-04-10 | 2005-10-06 | Andersen Jens T | Bacillus host cell |
KR102157964B1 (en) * | 2019-06-13 | 2020-09-22 | (주)제이비바이오텍 | African swine fever vaccine of porcine using CRISPR/Cas9 based Bacillus subtilis genome editing mechanism |
WO2021019102A2 (en) * | 2019-08-01 | 2021-02-04 | Acm Biolabs Pte Ltd | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes |
US11054429B1 (en) * | 2020-03-25 | 2021-07-06 | National University Of Singapore | SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein binding |
Non-Patent Citations (1)
Title |
---|
LEE SANGUN, BELITSKY BORIS R., BRINKER JAMES P., KERSTEIN KATHRYN O., BROWN DAVID W., CLEMENTS JOHN D., KEUSCH GERALD T., TZIPORI : "Development of a Bacillus subtilis -Based Rotavirus Vaccine", CLINICAL AND VACCINE IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 17, no. 11, 1 November 2010 (2010-11-01), pages 1647 - 1655, XP093040557, ISSN: 1556-6811, DOI: 10.1128/CVI.00135-10 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023004415A2 (en) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023004415A3 (en) | Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments | |
WO2018229236A3 (en) | Compositions comprising bacterial strains | |
EP4295902A3 (en) | Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of clostridium difficile infection | |
WO2018158306A8 (en) | Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection | |
MX2020009736A (en) | Compositions comprising bacterial strains. | |
MX2020006191A (en) | Therapeutic bacteriocins. | |
MX2021002719A (en) | Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains. | |
EP4289480A3 (en) | Macrocyclic broad spectrum antibiotics | |
PH12019501904A1 (en) | Macrocyclic broad spectrum antibiotics | |
WO2022067052A8 (en) | Probiotic bacillus compositions and methods of use | |
WO2020102901A8 (en) | Synthetic antibacterial compounds and uses thereof | |
WO2021004958A3 (en) | Compositions comprising bacterial strains | |
AU2020256283A8 (en) | Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof | |
MX2021005423A (en) | C10-alkylene substituted 13-membered macrolides and uses thereof. | |
WO2020146700A8 (en) | Lipid nanoparticles | |
WO2022011271A3 (en) | Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses | |
WO2019235782A8 (en) | Novel streptococcus suis bacteriophage str-sup-2, and use thereof for inhibiting proliferation of streptococcus suis strains | |
MX2022003871A (en) | Immunogenic compositions. | |
MX2022015299A (en) | Methods for stable genomic integration in recombinant microorganisms. | |
MX2021009443A (en) | Compositions containing bacillaene producing bacteria or preparations thereof. | |
MX2019006086A (en) | Use of a bacterial composition for treating foot infections of ungulates. | |
MX2020013857A (en) | Non-viable bifidobacterium bifidum bacteria and uses thereof. | |
WO2018236086A3 (en) | Novel aeromonas hydrophila bacteriophage aer-hyp-2 and use thereof in preventing proliferation of aeromonas hydrophila | |
WO2019039781A3 (en) | Novel aeromonas salmonicida bacteriophage aer-sap-2 and use thereof in inhibiting proliferation of aeromonas salmonicida bacteria | |
MX2022015439A (en) | Materials and methods for inhibiting a viral infection, including a coronavirus infection. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22846854 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |